


Remarks

This amendment is being made because the corrective amendment filed by facsimile on November 30, 1999 was not entered (the facsimile cover sheet requested that it be SUBSTITUTED for the earlier mailed amendment). The integrin of claim 1 has been limited to the specific CD11/CD18 integrins at page 4, lines 13-15, defined by claim 5. The amendment mailed November 15, 1999, contains an error in that the reference throughout the claims to the general class of "CD11/CD18" integrins includes a "d", which is incorrect, since this is one type of CD11/CD18 (originally presented in claim 5) makes dependent claim 5 have improper antecedent basis. The Amendment mailed November 15, 1999 also excluded the elected species. It is presumed the November 30, 1999 amendment, which corrected these errors, was not entered since the phrase "CD11/CD18" does not have literal support at page 4. This phrase has been eliminated from the claims as newly amended, and claim 1 limited to the named species of claim 5. Claim 5 was amended to delete Mac-1, the subject of claim 6, since otherwise claim 5 would not further limit the amended claim 1.

U.S.S.N.: 08/823,999
Filed: March 25, 1997
AMENDMENT

The November 30, 1999 amendment also proposed to limit claim 8 to antibodies and antibody fragments. The claim has again been amended to do so. Since the examiner rejected the claims as not enabled for anything other than antibodies, this amendment should be entered on the basis that it places this claim in better condition for appeal.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Date: June 19, 2000
Arnall, Golden & Gregory, LLP
2800 One Atlantic Center
1201 W. Peachtree Street
Atlanta, Georgia 30309
(404) 873-8794 (Phone)
(404) 873-8795 (Fax)